Radek Spisek1, Zdena Gasova, Jirina Bartunkova. 1. Institute of Immunology, Charles University, 2nd Medical School, Prague, Czech Republic. radek.spisek@lfmotol.cuni.cz
Abstract
BACKGROUND: Chronic graft-versus-host disease (cGVHD) represents a major cause of morbidity and mortality after allogeneic bone marrow transplantation (BMT). Extracorporeal photochemotherapy (ECP), a technique used in the treatment of cutaneous T-cell lymphoma, has also shown clinical efficacy in the treatment of refractory cGVHD. STUDY DESIGN AND METHODS: In this study, the dynamics of dendritic cell (DC) activation were investigated during the process of photopheresis in patients treated for refractory cGVHD. RESULTS: It is reported that myeloid DCs can be isolated from the photopheretic products before retransfusion to the patient. It is shown that DCs in ECP product are in the immature state with respect to the phenotypic and functional characteristics. In contrast to the in vitro-generated monocyte-derived DCs and DCs not treated by 8-methoxypsoralen and UVA, they produce significant amounts of interleukin-10 (IL-10). They efficiently capture apoptotic lymphocytes and do not induce proliferation of T lymphocytes. They preserve the capacity to be activated by polyriboinosinic polyribocytidylic acid and lipopolysaccharide, however. ECP also induces rapid and massive apoptosis of alloreactive lymphocytes. A model of the potential implication of IL-10-producing DCs in the down regulation of harmful alloreactive immune reaction is presented. CONCLUSION: It is believed that this study provides a novel insight into the mechanisms of action of ECP in the control of cGVHD.
BACKGROUND: Chronic graft-versus-host disease (cGVHD) represents a major cause of morbidity and mortality after allogeneic bone marrow transplantation (BMT). Extracorporeal photochemotherapy (ECP), a technique used in the treatment of cutaneous T-cell lymphoma, has also shown clinical efficacy in the treatment of refractory cGVHD. STUDY DESIGN AND METHODS: In this study, the dynamics of dendritic cell (DC) activation were investigated during the process of photopheresis in patients treated for refractory cGVHD. RESULTS: It is reported that myeloid DCs can be isolated from the photopheretic products before retransfusion to the patient. It is shown that DCs in ECP product are in the immature state with respect to the phenotypic and functional characteristics. In contrast to the in vitro-generated monocyte-derived DCs and DCs not treated by 8-methoxypsoralen and UVA, they produce significant amounts of interleukin-10 (IL-10). They efficiently capture apoptotic lymphocytes and do not induce proliferation of T lymphocytes. They preserve the capacity to be activated by polyriboinosinic polyribocytidylic acid and lipopolysaccharide, however. ECP also induces rapid and massive apoptosis of alloreactive lymphocytes. A model of the potential implication of IL-10-producing DCs in the down regulation of harmful alloreactive immune reaction is presented. CONCLUSION: It is believed that this study provides a novel insight into the mechanisms of action of ECP in the control of cGVHD.
Authors: R Knobler; G Berlin; P Calzavara-Pinton; H Greinix; P Jaksch; L Laroche; J Ludvigsson; P Quaglino; W Reinisch; J Scarisbrick; T Schwarz; P Wolf; P Arenberger; C Assaf; M Bagot; M Barr; A Bohbot; L Bruckner-Tuderman; B Dreno; A Enk; L French; R Gniadecki; H Gollnick; M Hertl; C Jantschitsch; A Jung; U Just; C-D Klemke; U Lippert; T Luger; E Papadavid; H Pehamberger; A Ranki; R Stadler; W Sterry; I H Wolf; M Worm; J Zic; C C Zouboulis; U Hillen Journal: J Eur Acad Dermatol Venereol Date: 2014-01 Impact factor: 6.166
Authors: A Legitimo; R Consolini; A Failli; S Fabiano; W Bencivelli; F Scatena; F Mosca Journal: Clin Exp Immunol Date: 2007-03-26 Impact factor: 4.330
Authors: Christian M Capitini; Jessica P E Davis; Shannon M Larabee; Sarah Herby; Nicole M Nasholm; Terry J Fry Journal: Biol Blood Marrow Transplant Date: 2011-01-07 Impact factor: 5.742
Authors: M Di Renzo; P Sbano; G De Aloe; A L Pasqui; P Rubegni; A Ghezzi; A Auteri; M Fimiani Journal: Clin Exp Immunol Date: 2008-03 Impact factor: 4.330
Authors: Erin Gatza; Clare E Rogers; Shawn G Clouthier; Kathleen P Lowler; Isao Tawara; Chen Liu; Pavan Reddy; James L M Ferrara Journal: Blood Date: 2008-04-14 Impact factor: 22.113
Authors: Beatrice Drexler; Andreas Buser; Laura Infanti; Gregor Stehle; Joerg Halter; Andreas Holbro Journal: Transfus Med Hemother Date: 2020-05-19 Impact factor: 3.747